A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

October 17, 2024

Study Completion Date

May 1, 2026

Conditions

Chronic Hepatitis B Virus

Interventions

DRUG

TVAX-008

DRUG

Placebo

Trial Locations (1)

Peking University first hospital, Beijing

All Listed Sponsors

lead

Grand Theravac Life Sciences (Nanjing) Co., Ltd.

INDUSTRY